Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$15.85 USD
-0.19 (-1.18%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $15.85 0.00 (0.00%) 5:24 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
HIMS 15.85 -0.19(-1.18%)
Will HIMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HIMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HIMS
Eli Lilly: The Next $1 Trillion Market Cap Stock?
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
HIMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
Boston Scientific (BSX) Rides on Global Growth, Buyouts
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
Other News for HIMS
Hold Rating on Hims & Hers Health Amid Mixed Financial Signals
Hold Rating on Hims & Hers Health Amid Revenue Uptick and Market Uncertainties
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Hold Rating on Hims & Hers Health Amidst Revenue Growth and Strategic Expansion Uncertainties
Palantir, Uber report Q2 beats: Morning Buzz